The role of ximelagatran in the treatment of venous thromboembolism.
about
Evaluation of pre-existing antibody presence as a risk factor for posttreatment anti-drug antibody induction: analysis of human clinical study data for multiple biotherapeutics.Pre-existing Antibody: Biotherapeutic Modality-Based Review.Platelet factor 4/heparin antibody (IgG/M/A) in healthy subjects: a literature analysis of commercial immunoassay resultsPrimary prophylaxis of venous thromboembolism in surgical patients.
P2860
The role of ximelagatran in the treatment of venous thromboembolism.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The role of ximelagatran in the treatment of venous thromboembolism.
@ast
The role of ximelagatran in the treatment of venous thromboembolism.
@en
type
label
The role of ximelagatran in the treatment of venous thromboembolism.
@ast
The role of ximelagatran in the treatment of venous thromboembolism.
@en
prefLabel
The role of ximelagatran in the treatment of venous thromboembolism.
@ast
The role of ximelagatran in the treatment of venous thromboembolism.
@en
P2093
P2860
P356
P1476
The role of ximelagatran in the treatment of venous thromboembolism.
@en
P2093
Hiroko Kobayasi
Miyako Matsuo
Shunji Suzuki
Takefumi Matsuo
P2860
P356
10.1159/000083080
P478
34 Suppl 1
P50
P577
2005-01-01T00:00:00Z